Jeuveau

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: • Spread of Toxin Effects [ see Warnings and Precautions ( 5.1 ) ] • Hypersensitivity [ see Contraindications ( 4.1 ) and Warnings and Precautions ( 5.4 ) ] • Dysphagia and Breathing Difficulties [ See Warnings and Precautions ( 5.7 ) ] The most common adverse reactions are headache (12%), eyelid ptosis (2%), upper respiratory tract infection (3%), and increased white blood cell count (1%) ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Evolus at [1-877-386-5871] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In general, most adverse reactions occur within the first week following injection of JEUVEAU and while generally transient, may have a duration of several months or longer. Localized pain, infection, inflammation, tenderness, swelling, erythema, and/or bleeding/bruising may be associated with the injection. Needle-related pain and/or anxiety may result in vasovagal responses, including syncope and hypotension, which may require appropriate medical therapy. Local weakness of the injected muscle(s) represents the expected pharmacological action of botulinum toxin. However, weakness of nearby muscles may also occur due to spread of toxin effect [ see Warnings and Precautions ( 5.1 ) ]. Glabellar Lines The adverse reactions below reflect exposure to JEUVEAU in the treatment of glabellar lines in placebo-controlled trials [ See Clinical Studies ( 14 ) ]. Table 2. Adverse Reactions Reported at Higher Frequency (≥1%) in the JEUVEAU Group Compared to the Placebo Group JEUVEAU EV-001, EV-002 N=492 n (%) PLACEBO EV-001, EV-002, N=162 n (%) Headache 57 (12%) 21 (13%) Eyelid Ptosis 8 (2%) 0 (0%) Upper Respiratory Tract Infection 13 (3%) 1 (1%) White blood cell count increase 6 (1%) 0 (0%) Two multi-center, open label, 1-year repeat dose safety trials, EV-004 [NCT02184988] and EV-006 [NCT02428608], were also conducted with JEUVEAU. Both trials evaluated repeat treatments of 20 units of JEUVEAU, up to a maximum total of 80 units, for the treatment of moderate to severe glabellar lines in adult subjects. Of the 922 subjects enrolled, the median number of treatments was three. The adverse events profile was similar to that reported in single dose trials. 6.2 Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to prabotulinumtoxinA-xvfs in the studies described below, with the incidence of antibodies in other studies, or to other products may be misleading. Treatment with botulinum toxins may result in the formation of antibodies that may reduce the effectiveness of subsequent treatments by inactivating biological activity of the toxin. Among 1,414 subjects treated with prabotulinumtoxinA-xvfs, 2 subjects were found to have pre-existing antibodies and 2 subjects had treatment-emergent antibodies.

4 CONTRAINDICATIONS • Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation ( 4.1 ) • Infection at the injection site ( 4.2 ) 4.1 Known Hypersensitivity to Botulinum Toxin JEUVEAU is contraindicated in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation [ See Warnings and Precautions ( 5.4 ) ]. 4.2 Infection at the Injection Site(s) JEUVEAU is contraindicated in the presence of infection at the proposed injection site(s).

11 DESCRIPTION PrabotulinumtoxinA-xvfs is an acetylcholine release inhibitor and a neuromuscular blocking agent. PrabotulinumtoxinA-xvfs is supplied as a sterile, vacuum-dried powder in a single-dose vial intended for intramuscular use after reconstitution. PrabotulinumtoxinA-xvfs is a 900 kDa botulinum toxin type A, produced from fermentation of Clostridium botulinum . The primary release procedure for JEUVEAU uses an animal based potency assay to determine the potency relative to a reference standard. The assay is specific to Evolus’ product, JEUVEAU. One Unit of JEUVEAU corresponds to the calculated median intraperitoneal lethal dose (LD 50 ) in mice. Due to specific details of this assay, Units of biological activity of JEUVEAU cannot be converted into Units of any other botulinum toxin or any toxin assessed with any other specific assay method. Each vial of JEUVEAU (prabotulinumtoxinA-xvfs) for injection contains 100 Units of botulinum toxin type A neurotoxin complex, human serum albumin (0.5 mg), and sodium chloride (0.9 mg) in a sterile, vacuum-dried form without a preservative.

2 DOSAGE AND ADMINISTRATION Glabellar Lines Administration: 0.1 mL (4 Units) by intramuscular injection into each of five sites, for a total dose of 20 Units ( 2.2 , 2.3 ) 2.1 Instructions for Safe Use The potency Units of JEUVEAU (prabotulinumtoxinA-xvfs) for injection are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of JEUVEAU cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method [ see Warnings and Precautions ( 5.2 ) and Description ( 11 ) ]. Retreatment of JEUVEAU should be administered no more frequently than every three months. Consideration of the cumulative dose is necessary when treating adult patients with JEUVEAU for glabellar lines if other botulinum toxin products are or have been used to treat other indications approved for those products. The safe and effective use of JEUVEAU depends upon proper storage of the product, selection of the correct dose, and proper reconstitution and administration techniques. Physicians administering JEUVEAU must understand the relevant neuromuscular and/or orbital anatomy of the area involved and any alterations to the anatomy due to prior surgical procedures [ see Warnings and Precautions ( 5.4 ) ]. 2.2 Preparation and Dilution Technique JEUVEAU is supplied in a single-dose 100 Unit vial. Prior to intramuscular injection, reconstitute each vacuum-dried vial of JEUVEAU with only sterile, preservative-free 0.9% Sodium Chloride Injection, USP to obtain a reconstituted solution at a concentration of 4 Units/0.1 mL and a total treatment dose of 20 Units in 0.5 mL (see Table 1 ). Slowly inject the diluent into the vial. Discard the vial if a vacuum does not pull the diluent into the vial. Dispose of any unused saline. Gently mix JEUVEAU with 0.9% Sodium Chloride Injection USP by rotating the vial. JEUVEAU should be administered within 24 hours after reconstitution. During this time period, unused reconstituted JEUVEAU should be stored in a refrigerator between 2° to 8°C (36°F to 46°F) in the original carton to protect from light for up to 24 hours until time of use. Do not freeze reconstituted JEUVEAU. JEUVEAU vials are for single-dose only. After reconstitution, JEUVEAU should be used for only one injection session and for only one patient. Discard any remaining solution after administration. Table 1. Dilution Instructions for JEUVEAU Vials (100 Units) Diluent Preservative-free 0.9% Sodium Chloride Injection, USP Added to 100 Unit Vial Resulting Dose Units per 0.1 mL 2.5 mL 4 Units Reconstituted JEUVEAU should be clear, colorless, and free of particulate matter otherwise it should not be injected. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. 2.3 Administration Glabellar facial lines arise from the activity of the corrugator and orbicularis oculi muscles. These muscles move the brow medially and the procerus and depressor supercilii pull the brow inferiorly. This creates a frown or “furrowed brow”. The location, size, and use of the muscles vary markedly among individuals. Lines induced by facial expression occur perpendicular to the direction of action of contracting facial muscles. An effective dose for facial lines is determined by gross observation of the patient’s ability to activate the superficial muscles injected. In order to reduce the complication of eyelid ptosis the following steps should be taken: • Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes. • Lateral corrugator injections should be placed at least 1 cm above the bony supraorbital ridge. • Ensure the injected volume/dose is accurate and where feasible kept to a minimum. • Avoid injecting JEUVEAU closer than 1 centimeter above the central eyebrow. Draw at least 0.5 mL of the properly reconstituted JEUVEAU into a sterile syringe and expel any air bubbles in the syringe barrel. Remove the needle used to reconstitute the product and attach a 30-33 gauge needle. Confirm the patency of the needle. Inject a dose of 0.1 mL (4 Units) intramuscularly into each of five sites: the inferomedial and superior middle of each corrugator, and one in the mid-line of the procerus muscle for a total dose of 20 Units (See Figure 1 ). Figure 1 Figure 1-2

10 OVERDOSAGE There is no information regarding overdose from clinical studies of JEUVEAU. Excessive doses of JEUVEAU (prabotulinumtoxinA-xvfs) injection may be expected to produce neuromuscular weakness with a variety of symptoms. Symptoms of overdose are likely not to be present immediately following injection. Should accidental injection or oral ingestion occur, or overdose be suspected, these patients should be considered for further medical evaluation and appropriate medical therapy immediately instituted, which may include hospitalization. The person should be medically supervised for several weeks for signs and symptoms of systemic muscular weakness which could be local or distant from the site of injection [ see Boxed Warning and Warnings and Precautions ( 5.1 ) ]. If the musculature of the oropharynx and esophagus are affected, aspiration may occur which may lead to development of aspiration pneumonia. If the respiratory muscles become paralyzed or sufficiently weakened, intubation and assisted respiration may be necessary until recovery takes place. Supportive care could involve the need for a tracheostomy and/or prolonged mechanical ventilation, in addition to other general supportive care. In the event of overdose, antitoxin raised against botulinum toxin is available from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. However, the antitoxin will not reverse any botulinum toxin-induced effects already apparent by the time of antitoxin administration. In the event of suspected or actual cases of botulinum toxin poisoning, please contact your local or state Health Department to process a request for antitoxin through the CDC. If you do not receive a response within 30 minutes, please contact the CDC directly at 1-770-488-7100. More information can be obtained at http://www.cdc.gov/ncidod/srp/drugs/formulary.html#1a.

7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with JEUVEAU (prabotulinumtoxinA-xvfs) for injection. However, the potential for certain drugs to potentiate the effects of JEUVEAU warrant consideration given the potential risks involved and should be used with caution. • Aminoglycosides or other agents interfering with neuromuscular transmission • Anticholinergic drugs • Botulinum neurotoxin products • Muscle relaxant Closely observe patients receiving concomitant treatment of JEUVEAU and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants because JEUVEAU’s effect may be potentiated ( 7 )

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action JEUVEAU blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, JEUVEAU produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and extrajunctional acetylcholine receptors may develop. There is evidence that reinnervation of the muscle may occur, thus slowly reversing muscle denervation produced by JEUVEAU. 12.2 Pharmacodynamics No formal pharmacodynamic studies have been conducted with JEUVEAU. 12.3 Pharmacokinetics Using currently available analytical technology, it is not possible to detect JEUVEAU in the peripheral blood following intramuscular injection at the recommended doses. No drug interaction studies have been conducted with JEUVEAU.

12.1 Mechanism of Action JEUVEAU blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, JEUVEAU produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and extrajunctional acetylcholine receptors may develop. There is evidence that reinnervation of the muscle may occur, thus slowly reversing muscle denervation produced by JEUVEAU.

12.2 Pharmacodynamics No formal pharmacodynamic studies have been conducted with JEUVEAU.

12.3 Pharmacokinetics Using currently available analytical technology, it is not possible to detect JEUVEAU in the peripheral blood following intramuscular injection at the recommended doses. No drug interaction studies have been conducted with JEUVEAU.

20230428

8

3 DOSAGE FORMS AND STRENGTHS • For injection: 100 Units, vacuum-dried powder in a single-dose vial for reconstitution with preservative-free 0.9% Sodium Chloride Injection, USP. For Injection: 100 Units vacuum-dried powder in a single-dose vial ( 3 )

Jeuveau Prabotulinum Toxin Type A BOTULINUM TOXIN TYPE A BOTULINUM TOXIN TYPE A ALBUMIN HUMAN SODIUM CHLORIDE

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been conducted to evaluate the carcinogenic, mutagenic, or impairment of fertility potential of JEUVEAU.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been conducted to evaluate the carcinogenic, mutagenic, or impairment of fertility potential of JEUVEAU.

BLA761085

Jeuveau

Prabotulinum Toxin Type A

72301-595

HUMAN PRESCRIPTION DRUG

INTRAMUSCULAR

PRINCIPAL DISPLAY PANEL - Carton Label Carton Label Principal Panel prabotulinumtoxinA-xvfs Jeuveau ® for Injection 100 UNITS/VIAL For Intramuscular Use 1 Single-Dose Vial ATTENTION: Dispense the enclosed Medication Guide to each patient Designed by Evolus Left Panel WARNING: Dosing units of botulinum toxins are not interchangeable between commercial products. Store unopened vial refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. DO NOT FREEZE. Each vial of Jeuveau (prabotulinumtoxinA-xvfs) contains 100 Units of botulinum toxin type A neurotoxin complex, human serum albumin (0.5 mg), and sodium chloride (0.9 mg). No U.S. standard of potency. Vacuum-dried. Contains no preservative. Rx only Manufactured by : Evolus, Inc. Newport Beach, CA US License No. 2070 at : Daewoong Pharmaceuticals Seoul, Korea www.jeuveau.com NDC 72301-595-10 Made in Korea Right Panel Single-Dose Vial. Discard unused portion. Only reconstitute each vial with sterile, preservative-free 0.9% Sodium Chloride Injection, USP by slowly injecting diluent and gently rotating the vial. Store unused reconstituted JEUVEAU refrigerated between 2° to 8°C (36°F to 46°F) in the original carton to protect from light for up to 24 hours until time of use. Do not freeze reconstituted JEUVEAU. Discard 24 hours after reconstitution. Dosage and Dilution: See Prescribing Information. Principal Display Panel - Carton Label

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Advise patients to inform their doctor if they develop any unusual symptoms (including difficulty with swallowing, speaking, or breathing), or if any known symptom persists or worsens [ see Warnings and Precautions ( 5.1 , 5.4 ) ]. Inform patients that JEUVEAU injection may cause eye dryness. Advise patients to report symptoms of eye dryness (e.g., eye pain, eye irritation, photosensitivity, or changes in vision) to their doctor [ see Warnings and Precautions ( 5.9 ) ]. Inform patients that if loss of strength, muscle weakness, blurred vision, or drooping eyelids occur, they should avoid driving a car or engaging in other potentially hazardous activities. Manufactured by: Evolus Inc. 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660 U.S. License Number 2070 at: Daewoong Pharmaceutical Co., Ltd. 12, Bongeunsa-ro 114-gil, Gangnam-gu, Seoul, 06170 Korea ©2023 Evolus. All rights reserved. All Trademarks are the property of their respective owners. DWG-131 Rev. E Evolus Logo

MEDICATION GUIDE JEUVEAU (pronounced Jū vō) (prabotulinumtoxinA-xvfs) for Injection What is the most important information I should know about JEUVEAU? JEUVEAU may cause serious side effects that can be life threatening. Call your healthcare provider or get medical help right away if you have any of these problems after treatment with JEUVEAU: • Problems swallowing, speaking, or breathing. These problems can happen hours, days, or weeks after an injection of JEUVEAU if the muscles that you use to breathe and swallow become weak after the injection. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with JEUVEAU. o People with certain breathing problems may need to use muscles in their neck to help them breathe. These people may be at greater risk for serious breathing problems with JEUVEAU. o Swallowing problems may last for several months. People who cannot swallow well may need a feeding tube to receive food and water. If swallowing problems are severe, food or liquids may go into your lungs. People who already have swallowing or breathing problems before receiving JEUVEAU have the highest risk of getting these problems. • Spread of toxin effects. In some cases, the effect of botulinum toxin may affect areas of the body away from the injection site and cause symptoms of a serious condition called botulism. The symptoms of botulism include: o loss of strength and muscle weakness all over the body o blurred vision and drooping eyelids o trouble saying words clearly o trouble breathing o double vision o hoarseness or change or loss of voice o loss of bladder control o trouble swallowing These symptoms can happen hours, days, or weeks after you receive an injection of JEUVEAU. These problems could make it unsafe for you to drive a car or do other dangerous activities. See “What should I avoid while receiving JEUVEAU?” What is JEUVEAU? JEUVEAU is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines). It is not known if JEUVEAU is safe and effective for use in children. Do not receive JEUVEAU if you: • are allergic to JEUVEAU or any of the ingredients in JEUVEAU. See the end of the Medication Guide for a list of ingredients in JEUVEAU. • had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (MYOBLOC ® ), onabotulinumtoxinA (BOTOX ® , BOTOX ® COSMETIC), abobotulinumtoxinA (DYSPORT ® ), or incobotulinumtoxinA (XEOMIN ® ). • have a skin infection at the planned injection site. Before receiving JEUVEAU, tell your healthcare provider about all your medical conditions, including if you: • have a disease that affects your muscles and nerves (such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], Myasthenia gravis or Lambert-Easton syndrome). See “What is the most important information I should know about JEUVEAU?” • had any side effect from any botulinum toxin product in the past. • have or have had a breathing problem, such as asthma or emphysema. • have or have had swallowing problems. • have or have had bleeding problems. • have or have had heart problems. • have plans to have surgery. • have weakness of your forehead muscles, such as trouble raising your eyebrows. • have drooping eyelids. • have had surgery on your face. • have had dry eye with use of botulinum toxin products in the past. • are pregnant or plan to become pregnant. It is not known if JEUVEAU can harm your unborn baby. • are breastfeeding or plan to breastfeed. It is not known if JEUVEAU passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with JEUVEAU. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Using JEUVEAU with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received JEUVEAU in the past. Especially tell your healthcare provider if you: • have received any other botulinum toxin product in the last 4 months. • have received injections of botulinum toxin, such as onabotulinumtoxinA (BOTOX ® , BOTOX ® COSMETIC) rimabotulinumtoxinB (MYOBLOC ® ), abobotulinumtoxinA (DYSPORT ® ), or incobotulinumtoxinA (XEOMIN ® ). Be sure your healthcare provider knows exactly which product you received. Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist each time you get a new medicine. How will I receive JEUVEAU? • JEUVEAU is an injection that your healthcare provider will give you. • JEUVEAU is injected into your affected muscles. • JEUVEAU should not be received more than 1 time every 3 months. • Your healthcare provider may change your dose of JEUVEAU, until you and your healthcare provider find the best dose for you. • Your healthcare provider will tell you how often you will receive your dose of JEUVEAU injections. What should I avoid while receiving JEUVEAU? JEUVEAU may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving JEUVEAU. If this happens, do not drive a car, operate machinery, or do other dangerous activities. See “What is the most important information I should know about JEUVEAU?” What are the possible side effects of JEUVEAU? JEUVEAU can cause serious side effects, including: • See “What is the most important information I should know about JEUVEAU? • Allergic reactions. Symptoms of an allergic reaction to JEUVEAU may include: itching, rash, hives, wheezing, trouble breathing, or you may become dizzy or faint. Tell your healthcare provider or get emergency medical help right away if you develop wheezing or trouble breathing, or if you feel dizzy or faint. • Heart problems. Irregular heartbeat and heart attack that have caused death have happened in some people who received botulinum toxin products. • Eye problems. Dry eye, reduced blinking, and corneal problems have happened in some people who receive JEUVEAU to treat glabellar lines. Tell your healthcare provider if you develop eye pain or irritation, sensitivity to light, or changes in your vision. The most common side effects of JEUVEAU include: • headache • eyelid drooping • upper respiratory infection • increased white blood cell count in your blood These are not all the possible side effect of JEUVEAU. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of JEUVEAU. Medicines are sometime prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider or pharmacist for information about JEUVEAU that is written for healthcare professionals. What are the ingredients in JEUVEAU? Active ingredient: botulinum toxin type A Inactive ingredients: human serum albumin and sodium chloride Manufactured by: Evolus Inc., 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660 US License No. 2070 ©2023 Evolus Inc. All rights reserved. All trademarks are the property of their respective owners. This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: 04 2023

14 CLINICAL STUDIES Two randomized, multi-center, double-blind, placebo-controlled trials (EV-001 [NCT02334423] and EV-002 [NCT02334436]) of identical design were conducted to evaluate JEUVEAU for use in the temporary improvement of the appearance of moderate to severe glabellar facial lines. These trials enrolled 654 subjects, randomized 3 to 1 to a single treatment with JEUVEAU (n=492) or placebo (n=162). The trials enrolled healthy adults (ranging in age from 18 to 81) with glabellar lines of at least moderate severity at maximum frown. The trials excluded subjects who had ptosis, deep dermal scarring, or an inability to substantially lessen glabellar lines even by physically spreading the glabellar lines apart. Injection volume was 0.1 mL/injection site, for a dose/injection site in the active treatment groups of 4 Units. Subjects were injected intramuscularly at five sites, one in the procerus muscle and two in each corrugator supercilii muscle, for a total dose in the active treatment groups of 20 Units. The primary efficacy endpoint was measured at Day 30 and was defined as the proportion of subjects achieving ≥2-grade improvement from baseline at maximum frown, as assessed independently by both the investigator and the subject using the Glabellar Line Scale (GLS). The GLS is a 4-point grading scale (0=none, 1=mild, 2= moderate, 3=severe). The results of these two efficacy trials are presented below (See Table 3 ). The mean age was 51 years, with 68 subjects (10%) ≥ 65 years of age. Most of the subjects were women (91%), and a majority of the subjects were white (84%). Table 3. Trials EV-001 and EV-002: Composite Investigator and Subject Assessment of Glabellar Line Severity at Maximum Frown at Day 30 – Responder Rates (% of Subjects Achieving ≥ 2-Grade Improvement from Baseline) Trial JEUVEAU Placebo Trial EV-001 N=246 68% N=84 1% Trial EV-002 N=246 70% N=78 1%

8.5 Geriatric Use The two clinical trials of JEUVEAU included 68 subjects age 65 and greater. Although no differences in safety or efficacy were observed between older and younger subjects, clinical studies of JEUVEAU did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.

8.1 Pregnancy Risk Summary The limited available data on JEUVEAU use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. An embryofetal developmental study conducted with JEUVEAU in pregnant rats revealed no treatment-related effects to the developing fetus when JEUVEAU was administered intramuscularly during organogenesis at doses up to 12 times the maximum recommended human dose (MRHD) ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryofetal developmental study, intramuscular doses up to 4 Unit/kg JEUVEAU were administered to pregnant rats once daily during organogenesis (gestation days 6 to 16). No maternal or embryofetal toxicities were observed at doses up to 4 Unit/kg (12 times the MRHD of 20 Units, based on Unit/kg comparison).

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary The limited available data on JEUVEAU use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. An embryofetal developmental study conducted with JEUVEAU in pregnant rats revealed no treatment-related effects to the developing fetus when JEUVEAU was administered intramuscularly during organogenesis at doses up to 12 times the maximum recommended human dose (MRHD) ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryofetal developmental study, intramuscular doses up to 4 Unit/kg JEUVEAU were administered to pregnant rats once daily during organogenesis (gestation days 6 to 16). No maternal or embryofetal toxicities were observed at doses up to 4 Unit/kg (12 times the MRHD of 20 Units, based on Unit/kg comparison). 8.2 Lactation There is no information regarding the presence of prabotulinumtoxinA-xvfs in human or animal milk, its effects on the breastfed infant, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for JEUVEAU and any potential adverse effects on the breastfed infant from JEUVEAU or from the underlying maternal condition 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use The two clinical trials of JEUVEAU included 68 subjects age 65 and greater. Although no differences in safety or efficacy were observed between older and younger subjects, clinical studies of JEUVEAU did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

16 HOW SUPPLIED/STORAGE AND HANDLING JEUVEAU (prabotulinumtoxinA-xvfs) for injection is a vacuum-dried powder supplied in a single-dose vial in the following size: 100 Units (NDC 72301-595-10) Storage Unopened vials of JEUVEAU should be stored in a refrigerator between 2° to 8°C (36° to 46° F) in the original carton to protect from light.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines. [ See Warnings and Precautions ( 5.1 ) ] WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of all botulinum toxin products, including JEUVEAU, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. JEUVEAU is not approved for the treatment of spasticity or any conditions other than glabellar lines. ( 5.1 )